Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma C Thomson

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|May 23, 2016
Late Ebola virus relapse causing meningoencephalitis: a case reportMichael Jacobs, Alison Rodger, David J Bell, et al.
Genome Research|March 16, 2021
Subgenomic RNA identification in SARS-CoV-2 genomic sequencing dataMatthew D Parker, Benjamin B Lindsey, Shay Leary, et al.
The Journal of Infection|June 3, 2023
Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistentDavid J Pascall, Elen Vink, Rachel Blacow, et al.
Epidemiology and Infection|January 22, 2024
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insightOlivia Bird, Eva P Galiza, David Neil Baxter, et al.
Science (New York, N.Y.)|March 10, 2021
SARS-CoV-2 within-host diversity and transmissionKatrina A Lythgoe, Matthew Hall, Luca Ferretti, et al.
Nature Immunology|December 23, 2021
Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infectionAlexander C Dowell, Megan S Butler, Elizabeth Jinks, et al.
Nature Microbiology|July 7, 2022
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwayBrian J Willett, Joe Grove, Oscar A MacLean, et al.
Nature Microbiology|September 16, 2022
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwayBrian J Willett, Joe Grove, Oscar A MacLean, et al.
The Journal of Infection|April 25, 2021
Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - A high risk community-hospital interfaceKathy K Li, Y Mun Woo, Oliver Stirrup, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|May 23, 2016
Late Ebola virus relapse causing meningoencephalitis: a case reportMichael Jacobs, Alison Rodger, David J Bell, et al.
Genome Research|March 16, 2021
Subgenomic RNA identification in SARS-CoV-2 genomic sequencing dataMatthew D Parker, Benjamin B Lindsey, Shay Leary, et al.
The Journal of Infection|June 3, 2023
Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistentDavid J Pascall, Elen Vink, Rachel Blacow, et al.
Epidemiology and Infection|January 22, 2024
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insightOlivia Bird, Eva P Galiza, David Neil Baxter, et al.
Science (New York, N.Y.)|March 10, 2021
SARS-CoV-2 within-host diversity and transmissionKatrina A Lythgoe, Matthew Hall, Luca Ferretti, et al.
Nature Immunology|December 23, 2021
Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infectionAlexander C Dowell, Megan S Butler, Elizabeth Jinks, et al.
Nature Microbiology|July 7, 2022
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwayBrian J Willett, Joe Grove, Oscar A MacLean, et al.
Nature Microbiology|September 16, 2022
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwayBrian J Willett, Joe Grove, Oscar A MacLean, et al.
The Journal of Infection|April 25, 2021
Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - A high risk community-hospital interfaceKathy K Li, Y Mun Woo, Oliver Stirrup, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Pageof 11